Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 21:47:101112.
doi: 10.1016/j.lanepe.2024.101112. eCollection 2024 Dec.

Gene therapy for spinal muscular atrophy: timing is key

Laurent Servais  1   2
Affiliations

Gene therapy for spinal muscular atrophy: timing is key

Laurent Servais. Lancet Reg Health Eur. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

LS has given consultancy/lectures for Biogen, Novartis, Roche, BioHaven, Scholar Rock, Zentech and Sysnav. He is part of the Data Safety Monitoring Board of NMB biopharma.

Similar articles

See all similar articles

Cited by

References

    1. Finkel R.S., Mercuri E., Darras B.T., et al. ENDEAR Study Group Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723–1732. - PubMed
    1. Govoni A., Gagliardi D., Comi G.P., Corti S. Time is motor neuron: therapeutic window and its correlation with pathogenetic mechanisms in spinal muscular atrophy. Mol Neurobiol. 2018;55:6307–6318. - PubMed
    1. Weiß C., Becker L., Friese J., et al. Efficacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH region: a population-based observational study. Lancet Reg Health Eur. 2024;47 doi: 10.1016/j.lanepe.2024.101092. - DOI - PMC - PubMed
    1. Gowda V., Atherton M., Murugan A., et al. Efficacy and safety of onasemnogene abeparvovec in children with spinal muscular atrophy type 1: real-world evidence from six infusion centres in the United Kingdom. Lancet Reg Health Eur. 2024;37 - PMC - PubMed
    1. Vrščaj E, Dangouloff T, Osredkar D, Servais L. Newborn screening programs for spinal muscular atrophy worldwide in 2023. J Neuromuscular Dis. In press. DOI 10.1177/22143602241288095. - PubMed